Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2018-06-19 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
CPEng
Regulatory Filings Classification · 95% confidence The document is a press release dated June 19, 2018, announcing positive results from an interim analysis of a Phase 3 clinical study (AB12003) for the drug masitinib in treating prostate cancer. It details the study design, the recommendation from the Independent Data Monitoring Committee (IDMC), and provides background information on the disease and the drug. This content structure—a formal announcement of clinical trial progress and results—is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical updates. Since it is not a full quarterly/annual report (10-K or IR), nor a transcript (CT), nor a formal regulatory filing like a DVA or DIRS, the most appropriate classification for a primary announcement of key operational/clinical results is Earnings Release (ER), as these announcements often contain the most material, time-sensitive operational news, even if not strictly financial results. Given the context of a pharmaceutical company announcing trial milestones, ER is the best fit among the provided options for a material operational update announcement.
2018-06-19 English
CPFR
Regulatory Filings Classification · 95% confidence The document is a press release dated June 19, 2018, announcing a positive recommendation from the Independent Data Monitoring Committee (IDMC) following an interim analysis of a Phase 3 clinical trial (AB12003) for masitinib in metastatic castration-resistant prostate cancer (mCRPC). This type of announcement, detailing clinical trial progress, interim results, and strategic decisions based on those results, is characteristic of an update intended for investors and the market regarding drug development. It is not a full Annual Report (10-K), a formal Audit Report (AR), a transcript (CT), or a standard Earnings Release (ER) which focuses on financial performance. It is a specific update on a key development program. While it contains elements that might be included in an Investor Presentation (IP), the format is a formal press release announcing a specific clinical milestone, which often falls under general regulatory/investor communications. Given the options, this is a specific corporate update related to R&D progress. Since there isn't a specific 'Clinical Trial Update' code, and it is a formal announcement of a significant development, it best fits the general category for significant corporate news that isn't strictly financial results or governance, making 'Regulatory Filings' (RNS) the most appropriate fallback for a non-standard, material announcement, or potentially 'Investor Presentation' (IP) if it were structured as a deck, but as a press release detailing trial progress, RNS is safer, or perhaps 'Capital/Financing Update' (CAP) if the implication is future value, but the core content is clinical. Given the nature of announcing trial progress and IDMC recommendations, which are material non-public information often disseminated via press release, 'RNS' (Regulatory Filings/General Announcement) is the most suitable general category for material, non-financial, non-governance updates.
2018-06-19 French
CPEng
Regulatory Filings Classification · 95% confidence The document is a press release from AB Science announcing a strategic decision regarding a marketing authorization application (MAA) for masitinib with the European Medicines Agency (EMA). It details the decision not to pursue reexamination and outlines plans to resubmit the application based on new data. This type of announcement, which communicates a significant development in regulatory or clinical strategy, is typically classified as an Earnings Release (ER) if it contains key financial highlights, or more generally as a Regulatory Filing (RNS) if it's a specific operational update that doesn't fit other categories. Since this is a detailed update on a regulatory pathway (MAA decision and resubmission plans) rather than a standard quarterly financial summary (ER) or a general regulatory filing (RNS), and it is not a formal report itself, it most closely aligns with an announcement of material information. Given the options, and since it is a specific operational/regulatory update that is not a formal report (like 10-K or IR), it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for specific operational announcements not covered elsewhere. However, because it is a press release detailing key business/regulatory progress, it often overlaps with ER content, but ER is defined as 'initial announcement of quarterly/periodical financial results (key highlights only)'. This is not about financial results. Therefore, RNS is the most appropriate fallback for this specific regulatory/strategic update.
2018-05-28 English
CPFR
Regulatory Filings Classification · 91% confidence The document is a press release from AB Science detailing a strategic decision regarding the marketing authorization application (MAA) for masitinib in treating ALS. It discusses regulatory interactions (CHMP, EMA), future submission plans, and provides company background. This type of announcement, focusing on regulatory strategy, clinical data updates, and future filing intentions, is characteristic of an Investor Presentation (IP) or a general press release related to R&D/Regulatory progress. Since it is a detailed update on strategy and data presentation rather than a formal financial report (10-K, IR) or a simple announcement of a report's release (RPA), 'Investor Presentation' (IP) is the closest fit for a comprehensive strategic update aimed at investors, even if it's structured as a press release. It is not a Call Transcript (CT), Earnings Release (ER), or a formal regulatory filing form.
2018-05-28 French
Rapport Financier Annuel 2017
Annual Report Classification · 100% confidence The document is explicitly titled 'RAPPORT FINANCIER ANNUEL DU GROUPE AB SCIENCE AU 31 DECEMBRE 2017' (Annual Financial Report). It contains a comprehensive summary including the management report, consolidated financial statements, company accounts, and audit reports. This matches the definition of an Annual Report (10-K equivalent for non-US entities). FY 2017
2018-04-30 French
CPFR
Regulatory Filings Classification · 90% confidence The document is a press release from AB Science announcing that the European Medicines Agency's Committee for Human Medicinal Products (CHMP) issued a negative opinion regarding the marketing authorization application for masitinib for ALS treatment. The company states its intention to request a review ('réexamen du dossier'). This type of announcement, detailing regulatory feedback on a drug application, is a specific corporate update. It is not a full Annual Report (10-K), an Earnings Release (ER), a Call Transcript (CT), or a standard Audit Report (AR). Since it concerns a significant regulatory decision impacting the company's pipeline and future commercial prospects, and it is presented as a formal press release detailing a specific event, it fits best under the general category of Regulatory Filings (RNS) as a miscellaneous, non-standard announcement, or potentially a Legal/Regulatory update, though LTR is usually for lawsuits. Given the options, RNS serves as the best fit for a specific regulatory outcome announcement that isn't a standard financial report or management change. The document length (7216 chars) is substantial enough that it is the report itself, not just an announcement of a report (RPA).
2018-04-19 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.